Haemonetics Names Chan Chief Operating Officer: A Strategic Move for Growth and Innovation

Haemonetics Corporation (NYSE: HAE), a global leader in medical technology, has announced the appointment of Frank Chan, Ph.D., as Executive Vice President and Chief Operating Officer (COO), effective April 7, 2025. This strategic move is expected to drive growth and innovation for the company, as Chan brings over 25 years of medical device and healthcare technology leadership experience to the role.



Chan's extensive background in research and development, regulatory affairs, global manufacturing, and supply chain operations will be invaluable in enhancing Haemonetics' operational efficiency and effectiveness. His experience at medtronic plc, where he served as President of Acute Care & Monitoring, demonstrates a strong understanding of global markets and a proven track record in driving growth and innovation.

The appointment of Frank Chan aligns with Haemonetics' strategic goals and long-term vision of improving the quality, effectiveness, and efficiency of care. His expertise in operational management, combined with his experience in medical device development, will be crucial in driving growth and innovation for the company.

In addition to the appointment of Frank Chan, haemonetics has also appointed Roy Galvin as Executive Vice President and Chief Commercial Officer, effective immediately. Galvin, who joined Haemonetics in 2022 as President, Global Plasma and Blood Center, will now oversee the company's global commercialization initiatives across its full product portfolio.

Galvin's appointment is expected to accelerate the adoption of Haemonetics' products and technologies, particularly in the attractive interventional cardiology market. The acquisition of OpSens, Inc., a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, is a testament to this strategy. The acquisition of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate, will enable Haemonetics to expand its leadership in interventional cardiology and strengthen its foundation for additional growth and diversification.

OpSens' core products, such as the SavvyWire® and OptoWire®, offer strong competitive advantages with a total addressable market of approximately $1 billion. These products are well-positioned for long-term growth and will benefit from Haemonetics' commercial success with its VASCADE® Vascular Closure portfolio, combined with extensive existing commercial and clinical infrastructure. This will accelerate customer access to OpSens' products, with the potential to make SavvyWire the leading guidewire for TAVR procedures in the U.S. Additionally, Haemonetics' presence in high-growth international markets will enable further penetration of OpSens products in these regions.

In conclusion, the appointment of Frank Chan as Executive Vice President and Chief Operating Officer, along with the expansion of Roy Galvin's role to include the Global Hospital business, is a strategic move for haemonetics corporation. These appointments align with the company's strategic goals and long-term vision, and are expected to drive growth and innovation in the medical technology sector. The acquisition of OpSens, Inc. further strengthens Haemonetics' position in the interventional cardiology market and sets the stage for continued success.